Tanvex BioPharma Inc (泰福生技), which focuses on supplying safe and affordable biosimilars, has obtained marketing approval in Canada for its TX01, a biosimilar of Neupogen (filgrastim), the company said yesterday.
Tanvex has signed contracts with Canada-based Mint Pharmaceuticals Inc authorizing the firm to sell TX01 in Canada, it said in a statement.
It is not known when sales of the drug would begin, as discussions with importers are required first and the COVID-19 pandemic might disrupt distribution, Tanvex said.
The prices for TX01 have yet to be decided, as the company still has to negotiate with private insurers, it said.
The gap between the prices of brand drugs and biosimilars is smaller than between brand drugs and generic drugs, as biosimilars require more research and development, and are more complex than generic drugs, Tanvex said.
Sales in Canada of Neupogen and its biosimilars reached more than C$100 million (US$80.68 million) in the 12 months to June, Tanvex said.
Amgen Inc’s Neupogen is used to treat chemotherapy-induced neutropenia and decreases the incidence of infection caused by febrile neutropenia, the company said.
Amgen filed a patent infringement claim against Tanvex in July 2019, but Tanvex reached an agreement with Amgen in March last year.
The company declined to reveal how much it agreed to pay Amgen.
“The expense was lower than the legal expenses if we had chosen to continue engaging in a lawsuit with Amgen,” a company official said by telephone yesterday.
Tanvex said obtaining approval in Canada has made it more confident of receiving approval from the US Food and Drug Administration (FDA), adding that it applied for a biologics license with the agency in October 2018.
The company expects to gain approval from the US FDA in the third quarter of next year, it said.
Tanvex’s cumulative revenue totaled NT$560,000 (US$19,989) for the first three quarters, up 86 percent from a year earlier.
For the first two quarters, it registered a net loss of NT$793 million, less than its net loss of NT$1.17 billion a year earlier, company data showed.
Taichung reported the steepest fall in completed home prices among the six special municipalities in the first quarter of this year, data compiled by Taiwan Realty Co (台灣房屋) showed yesterday. From January through last month, the average transaction price for completed homes in Taichung fell 8 percent from a year earlier to NT$299,000 (US$9,483) per ping (3.3m²), said Taiwan Realty, which compiled the data based on the government’s price registration platform. The decline could be attributed to many home buyers choosing relatively affordable used homes to live in themselves, instead of newly built homes in the city’s prime property market, Taiwan Realty
The government yesterday approved applications by Alphabet Inc’s Google to invest NT$27.08 billion (US$859.98 million) in Taiwan, the Ministry of Economic Affairs said in a statement. The Department of Investment Review approved two investments proposed by Google, with much of the funds to be used for data processing and electronic information supply services, as well as inventory procurement businesses in the semiconductor field, the ministry said. It marks the second consecutive year that Google has applied to increase its investment in Taiwan. Google plans to infuse NT$25.34 billion into Charter Investments Ltd (特許投資顧問) through its Singapore-based subsidiary Fructan Holdings Singapore Pte Ltd, and
JET JUICE: The war on Iran’s secondary effects have seen fuel prices skyrocket, knocking flight schedules down to earth in return as airlines struggle with costs Airline passengers should brace for more irritation in the next few months as carriers worldwide cancel flights and ground planes to cope with stratospheric increases in jet-fuel prices. Dutch flag carrier KLM is the latest company to cut its schedule, saying on Thursday that it would scrap 80 return flights at Amsterdam’s Schiphol Airport in the coming month. That puts it in the same league as United Airlines Holdings Inc, Deutsche Lufthansa AG and Cathay Pacific Airways Ltd, which have all pruned itineraries to mitigate costs. Global capacity for next month has been reduced by about 3 percentage points, with all
FORESEEABLE CONSEQUENCES: New technology always comes with new innovations by the iniquitous in exploiting users for financial gain or more nefarious ends Artificial intelligence (AI) “agents” say they can save users time and energy by automating tasks, but the growing power of systems such as OpenClaw is putting cybersecurity experts on edge. Powered by a wave of hype, OpenClaw today says it has more than three million users worldwide. The system allows users to create so-called agents, tools based on a large language model (LLM) such as OpenAI’s ChatGPT or Anthropic PBC’s Claude, that can carry out online tasks. “We’ve moved from an AI you could talk with via a chatbot to an agentic AI, which can take action... the threat and the risks are
RSS